Neutrophil oxidative metabolism in Down syndrome patients with congenital heart defects

Area of Science:

• Genetics and Molecular Biology
• Cardiology
• Biochemistry

Background:

• Down syndrome (DS) is characterized by trisomy 21, leading to elevated cytosolic superoxide dismutase (SOD-1) activity.
• Congenital heart defects (CHD) affect approximately 40% of individuals with Down syndrome.
• The role of SOD1 in the DS phenotype, particularly concerning CHD, remains unclear, though SOD1 is a known molecular marker for DS.

Purpose of the Study:

• To investigate whether the presence of congenital heart defects (CHD) influences the expression and activity of redox-related enzymes in patients with Down syndrome (DS).
• To explore the potential link between altered oxidative metabolism and the occurrence of CHD in individuals with DS.

Main Methods:

• Comparative analysis of enzyme expression and activity (SOD, GPx, MPO, CAT) in neutrophils from four groups: DS without CHD, DS with CHD, CHD without DS, and controls.
• Measurement of intracellular hydrogen peroxide concentration and superoxide release in neutrophils.
• Statistical evaluation of biochemical and cellular parameters across the experimental groups.

Main Results:

• Patients with Down syndrome, regardless of CHD status, exhibited increased SOD and glutathione peroxidase (GPx) levels and activity.
• Myeloperoxidase (MPO) and catalase (CAT) levels and activity, along with intracellular hydrogen peroxide, showed no significant differences among the groups.
• A notable decrease in superoxide release was observed in individuals with DS, and no significant differences in measured parameters were found between DS patients with and without CHD.

Conclusions:

• The study suggests that congenital heart defects in Down syndrome are not a consequence of altered redox metabolism specific to the disease.
• Elevated SOD and GPx activity in DS patients appear independent of the presence or absence of CHD, indicating a baseline metabolic characteristic of DS.